Increasing Number of Treatments to Benefit the U.S. Uterine Fibroid Market


Posted July 24, 2021 by shriya

US Uterine Fibroid Market expected to reach USD 39,993.2 million at growing CAGR of 3.24% By 2022.

 
U.S. Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027

Market Synopsis

The U.S. uterine fibroid market is anticipated to garner USD 39,993.2 million with 3.24% CAGR during the forecast period (2016-2022). According to a report by Market Research Future, the growth in the U.S. uterine fibroid market can be credited to the change in dietary pattern. Also termed as myomas or leiomyoma, uterine fibroids are referred to as the abnormal growth that develops on the wall of a woman’s uterus. Uterine fibroids are generally noncancerous growths and can cause symptoms such as pain in the lower back or pelvis, heavy bleeding during or between the menstrual cycle, increased cramping during menstruation, and enlargement of the abdomen.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2394

Drivers and Constraints Impacting the Market

The uterine fibroid market in the U.S. is witnessing a surge mainly due to the rising prevalence due to heredity coupled with the increasing number of treatments to cure the particular disease. With change in the lifestyle and dietary pattern, the market is estimated to flourish. Moreover, the accelerating number of hysterectomy surgeries is contributing to the market growth in the U.S. More than 200,000 hysterectomies are estimated to be performed every year. Several technological advancements have been made in order to treat uterine fibroids. With the evolution of minimally invasive surgeries, the market is expected to witness a boom. Benefits of such procedures such as reduced chances of infections, minimal recovery time, and shorter hospital stays are attracting patients to adopt such treatment procedures. Advancements in technology has also contributed to the market growth largely. For instance, the Halt Medical, Inc. had introduced Acessa Guidance System in 2016 which enhances the electromagnetic tracking technology and radiofrequency ablation in order to treat uterine myomas laparoscopically.

FDA has declared that power morcellators can result in complications such as spreading metastatic leiomyosarcoma cancer tissue. This is considered to slowdown the market growth to a great extent. Moreover, availability of alternative treatments is considered to dampen the market growth in the coming years.

U.S. Uterine Fibroid Market: Segmental Analysis

The U.S. uterine fibroid market has been segmented on the basis of type, type, diagnosis, and treatment.

By mode of type, the U.S. uterine fibroid market has been segmented into intramural fibroids, subserosal fibroids, submucosal fibroids, and others.

By mode of diagnosis, the U.S. uterine fibroid market has been segmented into computed tomography, medical resonance imaging scanners, ultrasounds, and others.

By mode of treatment, the U.S. uterine fibroid market has been segmented into magnetic resonance guided focused ultrasound, uterine fibroid embolization, endometrial ablation, myolysis, hysterectomy, and myomectomy.

Regional Insights

The prevalence of uterine fibroid is higher in the U.S. due to its high prevalence caused mainly due to changing lifestyle of the people. Texas, California, New York, and Florida are some of the places in the U.S. presumed to witness the highest prevalence of uterine fibroids. Moreover, the presence of major market players coupled with technological advancements made in the U.S. are further estimated to push the market. With rising patient pool undergoing hormonal disorders and growing incidences of uterine cancer are some of the other factors contributing to the growth of the market during the assessment period. Also, well established healthcare infrastructure, rising awareness among the population, and easy accessibility to latest technologies owing to the presence of ambulatory surgical centers and clinics and high number of hospitals are influencing the market growth to a great extent.

Industry Updates

August 31, 2018: Gynesonics has recently received the US FDA 510(k) clearance in order to market Sonata sonography-guided transcervical fibroid system for ablation of uterine fibroids. The Sonata System comprises a breakthrough integrated technology, and is regarded as the first intrauterine ultrasound system with a proprietary radiofrequency ablation device.

Competitive Dashboard

The prominent players operating the U.S. uterine fibroid market are Boston Scientific Corporation (US), Hologic (U.S.), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Cook Medical Inc. (US), AstraZeneca (England), and others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Akash Anand
Country United States
Categories Publishing , Research , Technology
Tags US Uterine Fibroid Market
Last Updated July 24, 2021